Glycemic ControlInsulin therapy

Clinical evidence dossier

Insulin therapy

Blood glucose

Evidence signal

Authoritative evidence signal

strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
2
Reported effects
18

Clinical conclusion

Insulin therapy has a small positive evidence signal for Blood glucose, but the clinical interpretation is limited.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Mean difference

-21.01 to 18.58 %

2 eligible estimates12–12 weeksObserved median: -1.2150000000000016 %

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
1
Magnitude-eligible effects
2

Consistency

Authoritative consistency classification

mixed

Positive
1
No effect
0
Mixed
1
Negative
1

Population and applicability

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Young Adult (19–39)
  • Middle Aged (40-64)
  • Older Adults (65+)
  • Male
  • Female
  • with T1 Diabetes
  • Hospitalized patients with type 2 diabetes.
  • Patients requiring insulin therapy for glycemic control.
  • Adults diagnosed with type 2 diabetes
  • Patients currently on premixed insulin therapy

Limitations

  • 1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.
  • Upstream consistency scoring indicates mixed findings across the evidence.
  • Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.
  • 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
  • 3 of 3 studies with duration data have follow-up of 12 weeks or less.
  • 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence